No Data
No Data
昭衍新藥:董事會召開日期
Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127.HK) fell more than 6%, leading the CRO concept, the possibility that the Federal Reserve will raise interest rates is still possible, and domestic innovative drugs are still in the adjustment cyc
CRO concept stocks continued to decline. As of press release, Zhaoyan Pharmaceutical (06127.HK) fell 5.98% to HK$9.28; Tiger Pharmaceuticals (03347.HK) fell 5.93% to HK$30.15; Kanglong Chemical (03759.HK) fell 5.18% to HK$8.78; and Pharmaceuticals (02359.HK) fell 3.96% to HK$32.75.
Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under
Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under pressure in the short term; 2) the company continues to promote an integrated layout to enhance core business capabilities; 3) the number of projects in the segment continues to grow, and the market share maintains an advantage; 4) there are plenty of orders in hand, and the expansion of production capacity and personnel ensures order execution. (Mainichi Keizai Shimbun)
Zhaoyan New Pharmaceutical (603127): Revenue was basically flat for the full year of 2023, and the results of the internationalization strategy showed results
Revenue remained flat throughout the year, and the profit side was under pressure in the short term. Revenue for the full year of 2023 was $2,376 million (+4.78%), net profit attributable to mother of $397 million (-63.04%), net profit not attributable to mother of $338 million
Bank Rating | Lyon: Upgraded Tiger Pharmaceuticals and Zhaoyan New Drug Ratings Benefit from Innovative Drug Support Policies
Glonghui, April 11 | Lyon published a research report saying that the mainland has continuously introduced policies on innovative drugs in recent weeks, and it has been seen that investors' confidence in innovative drug manufacturers has improved. In the mainland clinical research industry, the bank believes that Tiger Pharmaceuticals and Zhaoyan New Pharmaceuticals can benefit more from the government's new support policy than their peers. The bank raised Tiger Pharmaceuticals's rating from “outperforming the market” to “outperforming the market”. The target price was raised from HK$31.4 to HK$37.3 as the transparency of its earnings growth would improve from FY2025. The bank also upgraded the new drug rating to “outperform the market”, and the target price was raised from HK$9.8 to HK$11
Zhaoyan Pharmaceutical (603127) 2023 Annual Report Review: Profitability Under Short-term Pressure, Internationalization Continues to Advance
Guide to this report: Profitability is under pressure in the short term, capacity construction is increasing, internationalization continues to advance, optimistic about long-term growth space, and maintaining the rating of increasing holdings. Key investment points: Maintain an increase in holdings rating. 2023 revenue of $2,376 billion (+4.78%)
No Data